Beyang Therapeutics Secures $30 Million in Series A Financing for Drug R&D
August 12, 2026 — 20:21 CST
This Data Is Locked!
This area is available only to Subscribers.
Beyang Therapeutics Co., Ltd. has successfully closed an oversubscribed Series A financing round, raising nearly $30 million to advance global clinical development of differentiated pipelines.... [DATA LOCKED]
UNLOCK DATA
Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals
